Date Title Description PDF
07 Nov 2024 On P&L The Company releases the press release related to the first nine months 2024 financial results Download
07 Nov 2024 On P&L The Company releases the first nine months 2024 financial results presentation Download
24 Oct 2024 On corporate transactions ROVI completes the strategic review of its CDMO business Download
31 Jul 2024 On P&L The Company releases the press release related to the first half 2024 financial results Download
31 Jul 2024 On P&L The Company releases the first half 2024 financial results presentation Download

Pages

Date Title Description PDF
23 Feb 2022 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors Download
23 Feb 2022 Annual Corporate Governance Report ROVI releases the 2021 Annual Corporate Governance Report Download
21 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 Download
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download
14 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 Download

Pages

Date Title Description PDF
12 Jun 2013 Convocatorias y Acuerdos de Juntas y Asambleas Generales Download
06 Jun 2013 Otros sobre negocio y situación financiera Download
24 Apr 2013 Información sobre resultados (2) Download
24 Apr 2013 Información sobre resultados Download
24 Apr 2013 Convocatorias y Acuerdos de Juntas y Asambleas Generales Download

Pages